Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
Tango plans to move the combo approach to a Phase 3 trial
National Cancer Institute/USC Norris Comprehensive Cancer Center
June 8, 2026
Europe Correspondent
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
Revolution Medicines’ experimental pancreatic cancer drug has been the star of the oncology field in recent weeks, with new data showing the medicine produced unprecedented outcomes for patients.
Its next act — this time as a co-lead — was revealed Monday.
Advertisement
Tango Therapeutics said that in an early-stage clinical trial, a combination of its drug vopimetostat along with Revolution’s daraxonrasib led to a durable responses in the large majority of pancreatic cancer patients who received both medicines.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
Monthly
$39
Totals $468 per year
Totals $468 per year
Starter
$30
for 3 months, then $399/year
Then $399/year
Annual
$399
Save 15%
Save 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A Quote
Savings start at 25%!
2-10 Users
$300
Annually per user
$300 Annually per user
To read the rest of this story subscribe to STAT+.
biotechnology, Cancer, drug development, Pharmaceuticals, STAT+
Submit a correction request Reprints
Europe Correspondent
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
Newsletter
Your morning rundown of the science, politics, and money driving biotech today
Please enter a valid email address.Sign Up
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.
Recommended
The Readout
The ReadoutJune 8, 2026
STAT Plus: Novo underwhelmed by drug it once fought Pfizer for
Biotech
BiotechJune 8, 2026
STAT Plus: J&J spends $1 billion to enter KRAS race for cancer treatments
Opinions+
Opinions+June 8, 2026
$2 million gene therapy cures require a financing model
Pharma
PharmaJune 6, 2026
STAT Plus: Lilly shares safety, tolerability data on its next-gen obesity drug
Pharma
PharmaJune 6, 2026